Objective 1: Estimate efficacy of medical management with oral letrozole 10 mg daily for three consecutive days followed by vaginal misoprostol 800 mcg for treatment of EPL

Objective 2: Assess side effects, adverse events, and patient acceptability associated with letrozole and misoprostol for medical management of EPL Our primary outcome is the percentage of participants with absence of a gestational sac on transvaginal ultrasound on Study Day 10. Our secondary outcome variables are additional interventions required for successful management of early pregnancy loss, side effects and adverse events following study intervention, and patient acceptability of study intervention. These will be assessed at multiple time points through weekly electronic surveys (Study Days 17 and 24), via phone call with participants on Study Day 30, and through chart review once participants have completed the study.

You may be eligible for this study if you meet the following criteria:

• Conditions: Medical Research
• Age: - 99 Years
• Gender: All